-
Manifesto defends Germany's iconic Bauhaus against 'populist attacks'
-
Walmart reports mixed results as gas prices drag on US sales growth
-
Kenya's Kipyegon ends season with hamstring injury
-
Wang downs Sindhu to break Indian hearts at badminton worlds
-
Nord Stream bomb suspect arrested while working on movie about attack: media
-
As Europe's rivers recede, shippers scramble to limit damage
-
German football fans plan widespread VAR protests
-
Alonso won't confirm Fernandez will remain at Chelsea after Man City link
-
Scorching summer triggers record rockfalls in Alps, scientist says
-
Milky Way's fastest star discovered spinning around black hole
-
Newly-crowned European champ Werro turns focus on 800m record
-
Kanye West planned concerts trigger frenzy in Russia
-
Hamilton 'fittest ever' as he chases eighth F1 title
-
Hungary music festival basks in post-Orban freedom
-
Stocks retreat as bond yield fears persist, oil rises
-
Vatican says 'serious concerns' over Israel-Lebanon deal implementation
-
ARKBRIDGE’s David Mali Highlights AI-Driven Risk Management at the Finance Magnates London Summit
-
Arteta confirms Arsenal want to sign defender after Konsa link
-
Zuckerberg buys Gothic castle in Ireland: spokesman
-
What's behind the UAE's decision to cut Iran trade ties?
-
Belgium's fire of the century now 'under control'
-
Barca seal Cancelo return to bolster defence
-
Evergrande's Xu Jiayin: from real-estate tycoon to life in prison
-
Germany reports record 14,000 heat-related deaths this summer
-
Spurs eyeing move for Man City's Savinho and Marmoush - reports
-
Alvarez 'focused' says new Atletico team-mate Romero
-
Springboks captain Kolisi to miss first All Blacks Test
-
West Ham warn fans about 'offensive' Solomon chant
-
Japan to launch probe for Mars moons in October: space agency
-
Huge questions loom over Prince Harry's shock return to UK
-
From beach to Bulls: relaxed Tsunoda savours rare F1 drive
-
BYDFi Joins Coinfest Asia 2026, Connecting with Institutions, Builders and Traders in Bali
-
Prince Harry: key dates in life of returning UK royal
-
Max Verstappen: Natural-born winner
-
North Korea launches missiles, Seoul says, after Trump floats Kim meet
-
Van Dijk urges Liverpool to make amends for 'unacceptable' season
-
Oil jumps on Iran war tensions, offsetting bond yield fears
-
All Blacks replace Tuipulotu with Holland for Springboks Test
-
Germany identifies far-right suspect in deadly 1970 antisemitic attack
-
Rain delays start of second day's play in England-Pakistan opener
-
PrimeXBT Expands Swap-Free Trading to PXTrader 2.0
-
Russian strikes kill 16 in Kyiv, surrounding region
-
Record number of locations in France top 40C over summer: AFP analysis
-
'It is tough': Indonesia battles wildfires, bracing for worse to come
-
Trump pledges 'economic warfare' on Iran, prompting Tehran derision
-
Seoul detects North Korean missile launches after Trump says to meet Kim
-
'Girl with a Pearl Earring' in Japan, perhaps for the last time
-
Thai, Myanmar military chiefs meet as post-coup thaw progresses
-
Russian strikes kill 13 in Kyiv, surrounding region
-
Asian stocks rally as US Treasury steps in to ease bond fears
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Anderson--AT